- Home
- FNLC vs TNGX Comparison
FNLC vs TNGX Comparison
Compare FNLC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- TNGX
- Stock Information
- Founded
- FNLC 1864
- TNGX 2014
- Country
- FNLC United States
- TNGX United States
- Employees
- FNLC N/A
- TNGX N/A
- Industry
- FNLC Major Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- TNGX Health Care
- Exchange
- FNLC Nasdaq
- TNGX Nasdaq
- Market Cap
- FNLC 263.4M
- TNGX 248.2M
- IPO Year
- FNLC 1999
- TNGX N/A
- Fundamental
- Price
- FNLC $24.19
- TNGX $2.22
- Analyst Decision
- FNLC
- TNGX Strong Buy
- Analyst Count
- FNLC 0
- TNGX 6
- Target Price
- FNLC N/A
- TNGX $12.20
- AVG Volume (30 Days)
- FNLC 14.3K
- TNGX 3.5M
- Earning Date
- FNLC 07-23-2025
- TNGX 05-12-2025
- Dividend Yield
- FNLC 5.95%
- TNGX N/A
- EPS Growth
- FNLC 1.61
- TNGX N/A
- EPS
- FNLC 2.52
- TNGX N/A
- Revenue
- FNLC $82,116,000.00
- TNGX $40,990,000.00
- Revenue This Year
- FNLC N/A
- TNGX N/A
- Revenue Next Year
- FNLC N/A
- TNGX N/A
- P/E Ratio
- FNLC $9.60
- TNGX N/A
- Revenue Growth
- FNLC 5.28
- TNGX 10.09
- 52 Week Low
- FNLC $22.11
- TNGX $1.03
- 52 Week High
- FNLC $31.05
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- FNLC 47.41
- TNGX 62.75
- Support Level
- FNLC $23.75
- TNGX $1.93
- Resistance Level
- FNLC $25.02
- TNGX $2.67
- Average True Range (ATR)
- FNLC 0.51
- TNGX 0.40
- MACD
- FNLC -0.06
- TNGX 0.07
- Stochastic Oscillator
- FNLC 38.97
- TNGX 59.59
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.